Healthcare Reports @johnnydanielrb-blog - Tumblr Blog

Metrorrhagia (Abnormal Uterine Bleeding) Global Clinical Trials Review, H2, 2015

Metrorrhagia (Abnormal Uterine Bleeding) Global Clinical Trials Review, H2, 2015 provides an overview of Metrorrhagia (Abnormal Uterine Bleeding) clinical trials scenario. This report provides top line data relating to the clinical trials on Metrorrhagia (Abnormal Uterine Bleeding). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Enquiry about report: http://www.researchbeam.com/metrorrhagia-abnormal-uterine-bleeding-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

Table of Content

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials 19

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 26

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials 31

Prominent Drugs 33

Clinical Trial Profile Snapshots 34

Appendix 65

Abbreviations 65

Definitions 65

Research Methodology 66

Secondary Research 66

About GlobalData 67

Disclaimer 67

Source 68

List of Tables

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Region, 2015* 6

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials, G7 Countries (%), 2015* 16

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials, E7 Countries (%), 2015* 20

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Phase, 2015* 23

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

List of Figures

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14

Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials, G7 Countries (%), 2015* 15

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Metrorrhagia (Abnormal Uterine Bleeding) to Women's Health Clinical Trials, E7 Countries (%), 2015* 19

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Metrorrhagia (Abnormal Uterine Bleeding) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

GlobalData Methodology 66

Source: http://www.researchbeam.com/metrorrhagia-abnormal-uterine-bleeding-global-clinical-trials-review-h2-2015-market

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Hypercholesterolemia - Pipeline Review, H2 2015

Hypercholesterolemia Pipeline Review, H2 2015, provides an overview of the Hypercholesterolemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Enquiry about report: http://www.researchbeam.com/hypercholesterolemia-pipeline-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Table of Content

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypercholesterolemia Overview 9

Therapeutics Development 10

Pipeline Products for Hypercholesterolemia - Overview 10

Pipeline Products for Hypercholesterolemia - Comparative Analysis 11

Hypercholesterolemia - Therapeutics under Development by Companies 12

Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 16

Hypercholesterolemia - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Hypercholesterolemia - Products under Development by Companies 21

Hypercholesterolemia - Products under Investigation by Universities/Institutes 26

Hypercholesterolemia - Companies Involved in Therapeutics Development 27

3SBio Inc. 27

Abeome Corporation 28

Aegerion Pharmaceuticals, Inc. 29

Amgen Inc. 30

AtheroNova Inc. 31

BioLingus AG 32

Catabasis Pharmaceuticals, Inc. 33

Cerenis Therapeutics Holding SA 34

CymaBay Therapeutics, Inc. 35

Daewon Pharm Co. Ltd. 36

DreamPharma Corp. 37

Dybly AG 38

Eli Lilly and Company 39

Esperion Therapeutics, Inc. 40

F. Hoffmann-La Roche Ltd. 41

Gemphire Therapeutics Inc. 42

Hanmi Pharmaceuticals, Co. Ltd. 43

Immune Response BioPharma, Inc. 44

Johnson & Johnson 45

Kadmon Corporation, LLC 46

Kowa Company, Ltd. 47

Merck & Co., Inc. 48

Novartis AG 49

Pfizer Inc. 50

Regeneron Pharmaceuticals, Inc. 51

RegenxBio Inc. 52

Sanofi 53

Serometrix, LLC 54

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 55

The Medicines Company 56

Thetis Pharmaceuticals LLC 57

Viking Therapeutics, Inc. 58

Zhejiang Hisun Pharmaceutical Co., Ltd. 59

Hypercholesterolemia - Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Combination Products 61

Assessment by Target 62

Assessment by Mechanism of Action 65

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

(aspirin + lisinopril + lovastatin) - Drug Profile 72

(atorvastatin calcium + TP-452) - Drug Profile 73

(bempedoic acid + ezetimibe) - Drug Profile 74

(ezetimibe + atorvastatin calcium) - Drug Profile 75

(ezetimibe + rosuvastatin calcium) - Drug Profile 76

AEM-28 - Drug Profile 77

AEM-2802 - Drug Profile 78

AEM-2814 - Drug Profile 79

AHRO-001 - Drug Profile 80

alirocumab - Drug Profile 82

ALN-PCSsc - Drug Profile 86

AM-0010 - Drug Profile 87

anacetrapib - Drug Profile 89

Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases - Drug Profile 91

Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile 92

aplexone - Drug Profile 93

bempedoic acid - Drug Profile 94

bococizumab - Drug Profile 96

BSN-272 - Drug Profile 97

CAT-2000 Series - Drug Profile 98

CAT-2003 - Drug Profile 99

CAT-2054 - Drug Profile 100

CER-001 - Drug Profile 101

colestilan chloride - Drug Profile 103

Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 104

DW-0929 - Drug Profile 105

DW-3102 - Drug Profile 106

DYB-186 - Drug Profile 107

EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 108

EP-80317 - Drug Profile 110

evinacumab - Drug Profile 111

evolocumab - Drug Profile 112

fenofibrate - Drug Profile 115

gemcabene calcium - Drug Profile 117

Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 118

HCP-1305 - Drug Profile 119

HGP-0816 - Drug Profile 120

HS-25 - Drug Profile 121

IR-1002 - Drug Profile 122

ISIS-APOCIIILRx - Drug Profile 123

J-17 - Drug Profile 124

KD-026 - Drug Profile 125

lomitapide mesylate - Drug Profile 127

LY-3015014 - Drug Profile 130

MBX-8025 - Drug Profile 131

MGL-3196 - Drug Profile 133

mipomersen sodium - Drug Profile 135

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 137

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 138

PCSK-9 - Drug Profile 139

PF-06678552 - Drug Profile 140

pitavastatin CR - Drug Profile 141

pradigastat sodium - Drug Profile 142

RGX-501 - Drug Profile 143

Small Molecule for Hypercholesterolemia - Drug Profile 144

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile 145

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 146

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 147

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 148

Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 150

ST-101 - Drug Profile 151

SX-PCK9 - Drug Profile 152

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 153

TP-452 - Drug Profile 154

VK-0214 - Drug Profile 155

VK-2809 - Drug Profile 156

volanesorsen sodium - Drug Profile 158

Hypercholesterolemia - Recent Pipeline Updates 160

Hypercholesterolemia - Dormant Projects 214

Hypercholesterolemia - Discontinued Products 219

Hypercholesterolemia - Product Development Milestones 221

Featured News & Press Releases 221

Appendix 230

Methodology 230

Coverage 230

Secondary Research 230

Primary Research 230

Expert Panel Validation 230

Disclaimer 231

Source: http://www.researchbeam.com/hypercholesterolemia-pipeline-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Womens Health - APAC Analysis and Market Forecasts

The Womens Health medical devices market encompasses treatments for conditions that are particular to the adult female anatomy. This includes abnormal uterine conditions, such as menorrhagia and uterine fibroids, as well as pelvic disorders such as female stress urinary incontinence. Moreover, there is a sub-segment of the female population that no longer desire to become pregnant, and seek permanent solutions to avoid conception.

Enquiry about report: http://www.researchbeam.com/womens-health-apac-analysis-and-forecasts-market/enquire-about-report

Scope

- Overview of womens health, including anatomy, epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.

- Annualized total womens health market revenue from 2011-2021 including adoption patterns in the APAC.

- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, and implications for the womens health market.

- Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and womens health devices in development.

- Analysis of the current and future market competition in the APAC womens health market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Table Of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Industry Overview

3.1 Overview

3.2 Indications

4 Unmet Needs

4.1 Overview

4.2 Endometrial Ablation/Resection Devices

5 Market Opportunity Analysis

5.1 Overview

5.2 Endometrial Ablation/Resection Devices

6 Market Drivers and Barriers

6.1 Endometrial Ablation/Resection

6.2 Uterine Fibroid Embolization Agents

7 Competitive Assessment

7.1 Overview

7.2 Classification Based on Features

8 Pipeline Assessment

8.1 Overview

8.2 Key Product Profiles

9 Clinical Trials to Watch

9.1 Overview

9.2 Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

11 Market Outlook

11.1 By Geography

11.1.1 By Region

12 Appendix

12.1 Bibliography

12.2 Abbreviations

Reasons to buy

- What Physicians Think quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading gynecologists, urogynecologists, interventional radiologists, and general surgeons from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Source: http://www.researchbeam.com/womens-health-apac-analysis-and-forecasts-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Inhalers - Medical Devices Pipeline Assessment, 2015

Inhalers - Medical Devices Pipeline Assessment, 2015 provides an overview of Inhalers currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalers pipeline products.

Enquiry about report: http://www.researchbeam.com/inhalers-medical-devices-pipeline-assessment-2015-market/enquire-about-report

Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 7

2 Introduction 8

2.1 Inhalers Overview 8

3 Products under Development 9

3.1 Inhalers - Pipeline Products by Stage of Development 9

3.2 Inhalers - Pipeline Products by Segment 10

3.3 Inhalers - Pipeline Products by Territory 11

3.4 Inhalers - Pipeline Products by Regulatory Path 12

3.5 Inhalers - Pipeline Products by Estimated Approval Date 13

3.6 Inhalers - Ongoing Clinical Trials 14

4 Inhalers - Pipeline Products under Development by Companies 15

4.1 Inhalers Companies - Pipeline Products by Stage of Development 15

4.2 Inhalers - Pipeline Products by Stage of Development 17

5 Inhalers Companies and Product Overview 19

5.1 Adamis Pharmaceuticals Corporation Company Overview 19

5.1.1 Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Advent Pharmaceuticals Pty Ltd Company Overview 22

5.2.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

5.3 Aespira Ltd. Company Overview 23

5.3.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23

5.4 Akela Pharma Inc. (Inactive) Company Overview 24

5.4.1 Akela Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

5.5 Alexza Pharmaceuticals, Inc. Company Overview 25

5.5.1 Alexza Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25

5.6 Bayer HealthCare AG Company Overview 28

5.6.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 28

5.7 Bellerophon Therapeutics LLC Company Overview 30

5.7.1 Bellerophon Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 Bespak Europe Ltd. Company Overview 31

5.8.1 Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview 31

5.9 Cipla Ltd. Company Overview 32

5.9.1 Cipla Ltd. Pipeline Products & Ongoing Clinical Trials Overview 32

5.10 CN Creative Company Overview 34

5.10.1 CN Creative Pipeline Products & Ongoing Clinical Trials Overview 34

5.11 Drexel University Company Overview 35

5.11.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 35

5.12 FocusStart Orthosensors Company Overview 36

5.12.1 FocusStart Orthosensors Pipeline Products & Ongoing Clinical Trials Overview 36

5.13 GlaxoSmithKline Plc Company Overview 37

5.13.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 37

5.14 Hovione FarmaCiencia SA Company Overview 39

5.14.1 Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview 39

5.15 MannKind Corporation Company Overview 40

5.15.1 MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview 40

5.16 Medihale Ltd. Company Overview 42

5.16.1 Medihale Ltd. Pipeline Products & Ongoing Clinical Trials Overview 42

5.17 Nanotherapeutics, Inc. Company Overview 43

5.17.1 Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43

5.18 Nektar Therapeutics Company Overview 45

5.18.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 45

5.19 North Carolina State University Company Overview 47

5.19.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 47

5.20 Novartis AG Company Overview 48

5.20.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 48

5.21 OPKO Health, Inc. Company Overview 52

5.21.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52

5.22 Pharmaxis Limited Company Overview 54

5.22.1 Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview 54

5.23 Respira Therapeutics, Inc. Company Overview 56

5.23.1 Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56

5.24 Sandoz International GmbH Company Overview 57

5.24.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 57

5.25 Sheffield Hallam University Company Overview 60

5.25.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 60

5.26 Shin Nippon Biomedical Laboratories, Ltd. Company Overview 61

5.26.1 Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 61

5.27 SHL Medical Company Overview 63

5.27.1 SHL Medical Pipeline Products & Ongoing Clinical Trials Overview 63

5.28 SkyePharma Plc Company Overview 65

5.28.1 SkyePharma Plc Pipeline Products & Ongoing Clinical Trials Overview 65

5.29 Teva Pharmaceutical Industries Limited Company Overview 67

5.29.1 Teva Pharmaceutical Industries Limited Pipeline Products & Ongoing Clinical Trials Overview 67

5.30 University of Kansas Company Overview 71

5.30.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 71

5.31 University of Texas Medical Branch at Galveston Company Overview 72

5.31.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 72

6 Inhalers- Recent Developments 73

7 Appendix 122

7.1 Methodology 122

7.2 About GlobalData 124

7.3 Contact Us 125

7.4 Disclaimer 125

Source: http://www.researchbeam.com/inhalers-medical-devices-pipeline-assessment-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#inhalers market #inhalers market market #inhalers #inhalers market size #inhalers market share #inhalers market trends #inhalers market forecast #inhalers market futures #inhalers market opportunities #inhalers market news #inhalers market research #inhalers market strategy #inhalers market application #inhalers market segmentation

Surgical Devices - Medical Devices Pipeline Assessment, 2015

Surgical Devices - Medical Devices Pipeline Assessment, 2015 provides an overview of Surgical Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Surgical Devices pipeline products.

Enquiry about report: http://www.researchbeam.com/surgical-devices-medical-devices-pipeline-assessment-2015-market/enquire-about-report

Scope

- Extensive coverage of the Surgical Devices under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Table Of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 8

1.2 List of Figures 18

2 Introduction 19

2.1 Surgical Devices Overview 19

3 Products under Development 20

3.1 Surgical Devices - Pipeline Products by Stage of Development 20

3.2 Surgical Devices - Pipeline Products by Segment 21

3.3 Surgical Devices - Pipeline Products by Territory 23

3.4 Surgical Devices - Pipeline Products by Regulatory Path 24

3.5 Surgical Devices - Pipeline Products by Estimated Approval Date 25

3.6 Surgical Devices - Ongoing Clinical Trials 26

4 Surgical Devices - Pipeline Products under Development by Companies 27

4.1 Surgical Devices Companies - Pipeline Products by Stage of Development 27

4.2 Surgical Devices - Pipeline Products by Stage of Development 32

5 Surgical Devices Companies and Product Overview 37

5.1 Adept Medical Limited Company Overview 37

5.1.1 Adept Medical Limited Pipeline Products & Ongoing Clinical Trials Overview 37

5.2 Anastom Surgical Company Overview 38

5.2.1 Anastom Surgical Pipeline Products & Ongoing Clinical Trials Overview 38

5.3 Apollo Endosurgery, Inc. Company Overview 39

5.3.1 Apollo Endosurgery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39

5.4 Applied Medical Resources Corporation Company Overview 40

5.4.1 Applied Medical Resources Corporation Pipeline Products & Ongoing Clinical Trials Overview 40

5.5 Arkis BioSciences Company Overview 47

5.5.1 Arkis BioSciences Pipeline Products & Ongoing Clinical Trials Overview 47

5.6 Bio DG Company Overview 49

5.6.1 Bio DG Pipeline Products & Ongoing Clinical Trials Overview 49

5.7 BioTex, Inc. Company Overview 50

5.7.1 BioTex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

5.8 Boston Scientific Corporation Company Overview 51

5.8.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 51

5.9 BriteSeed Company Overview 53

5.9.1 BriteSeed Pipeline Products & Ongoing Clinical Trials Overview 53

5.10 C. R. Bard, Inc. Company Overview 54

5.10.1 C. R. Bard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54

5.11 Cardica, Inc. Company Overview 56

5.11.1 Cardica, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56

5.12 Carnegie Mellon University Company Overview 65

5.12.1 Carnegie Mellon University Pipeline Products & Ongoing Clinical Trials Overview 65

5.13 CarpoNovum AB Company Overview 67

5.13.1 CarpoNovum AB Pipeline Products & Ongoing Clinical Trials Overview 67

5.14 Castle Surgical, Inc. Company Overview 70

5.14.1 Castle Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 70

5.15 CIVCO Medical Solutions Company Overview 71

5.15.1 CIVCO Medical Solutions Pipeline Products & Ongoing Clinical Trials Overview 71

5.16 Cologuard Ltd Company Overview 73

5.16.1 Cologuard Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

5.17 Control Medical Technology, LLC Company Overview 74

5.17.1 Control Medical Technology, LLC Pipeline Products & Ongoing Clinical Trials Overview 74

5.18 Core Essence Orthopaedics, LLC Company Overview 75

5.18.1 Core Essence Orthopaedics, LLC Pipeline Products & Ongoing Clinical Trials Overview 75

5.19 Cytori Therapeutics, Inc. Company Overview 76

5.19.1 Cytori Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 76

5.20 Ding Hwa Co., Ltd Company Overview 80

5.20.1 Ding Hwa Co., Ltd Pipeline Products & Ongoing Clinical Trials Overview 80

5.21 Embricon Limited Company Overview 81

5.21.1 Embricon Limited Pipeline Products & Ongoing Clinical Trials Overview 81

5.22 EndoEvolution, LLC Company Overview 82

5.22.1 EndoEvolution, LLC Pipeline Products & Ongoing Clinical Trials Overview 82

5.23 Ethicon Endo-Surgery, Inc. Company Overview 83

5.23.1 Ethicon Endo-Surgery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 83

5.24 Eximo Medical Ltd. Company Overview 84

5.24.1 Eximo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 84

5.25 Exploit Technologies Pte Ltd Company Overview 85

5.25.1 Exploit Technologies Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 85

5.26 Fogless International AB Company Overview 86

5.26.1 Fogless International AB Pipeline Products & Ongoing Clinical Trials Overview 86

5.27 Genicon, Inc. Company Overview 87

5.27.1 Genicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87

5.28 H. Lee Moffitt Cancer Center & Research Institute, Inc. Company Overview 88

5.28.1 H. Lee Moffitt Cancer Center & Research Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 88

5.29 Hadasit Medical Research Services & Development Ltd Company Overview 89

5.29.1 Hadasit Medical Research Services & Development Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

5.30 Hannover Medical School Company Overview 90

5.30.1 Hannover Medical School Pipeline Products & Ongoing Clinical Trials Overview 90

5.31 Harvard University Company Overview 92

5.31.1 Harvard University Pipeline Products & Ongoing Clinical Trials Overview 92

5.32 HemCon Medical Technologies, Inc. Company Overview 94

5.32.1 HemCon Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 94

5.33 Hospital for Special Surgery Company Overview 95

5.33.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 95

5.34 i360medical Limited Company Overview 97

5.34.1 i360medical Limited Pipeline Products & Ongoing Clinical Trials Overview 97

5.35 Insightra Medical Inc. Company Overview 98

5.35.1 Insightra Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 98

5.36 Intuitive Surgical, Inc. Company Overview 102

5.36.1 Intuitive Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 102

5.37 Inx Medical LLC Company Overview 106

5.37.1 Inx Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 106

5.38 IonMed Ltd. Company Overview 107

5.38.1 IonMed Ltd. Pipeline Products & Ongoing Clinical Trials Overview 107

5.39 IPI Singapore Company Overview 111

5.39.1 IPI Singapore Pipeline Products & Ongoing Clinical Trials Overview 111

5.40 Janus Development Group, Inc Company Overview 112

5.40.1 Janus Development Group, Inc Pipeline Products & Ongoing Clinical Trials Overview 112

5.41 Keren Medical Ltd. Company Overview 113

5.41.1 Keren Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 113

5.42 Kytogenics Pharmaceuticals, Inc. Company Overview 115

5.42.1 Kytogenics Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 115

5.43 Lumenis Ltd. Company Overview 116

5.43.1 Lumenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 116

5.44 MagniFeel Surgical Instruments Company Overview 118

5.44.1 MagniFeel Surgical Instruments Pipeline Products & Ongoing Clinical Trials Overview 118

5.45 Mayo Clinic. Company Overview 119

5.45.1 Mayo Clinic. Pipeline Products & Ongoing Clinical Trials Overview 119

5.46 Mecmaan Healthcare Ltd Company Overview 123

5.46.1 Mecmaan Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview 123

5.47 Medical University of South Carolina Company Overview 125

5.47.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 125

5.48 Medisse BV Company Overview 126

5.48.1 Medisse BV Pipeline Products & Ongoing Clinical Trials Overview 126

5.49 Medivur Company Overview 127

5.49.1 Medivur Pipeline Products & Ongoing Clinical Trials Overview 127

5.50 Medtronic plc Company Overview 128

5.50.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 128

5.51 Memorial Sloan Kettering Cancer Center Company Overview 132

5.51.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 132

5.52 Mercy Research and Development Company Overview 134

5.52.1 Mercy Research and Development Pipeline Products & Ongoing Clinical Trials Overview 134

5.53 Naviswiss AG Company Overview 135

5.53.1 Naviswiss AG Pipeline Products & Ongoing Clinical Trials Overview 135

5.54 NIH Office of Technology Transfer Company Overview 136

5.54.1 NIH Office of Technology Transfer Pipeline Products & Ongoing Clinical Trials Overview 136

5.55 Nitinol Devices and Components, Inc. Company Overview 138

5.55.1 Nitinol Devices and Components, Inc. Pipeline Products & Ongoing Clinical Trials Overview 138

5.56 NorthShore University Health System Company Overview 140

5.56.1 NorthShore University Health System Pipeline Products & Ongoing Clinical Trials Overview 140

5.57 NOvate Medical Technologies, LLC Company Overview 141

5.57.1 NOvate Medical Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 141

5.58 NovoGI LTD Company Overview 142

5.58.1 NovoGI LTD Pipeline Products & Ongoing Clinical Trials Overview 142

5.59 Novolock Ltd Company Overview 144

5.59.1 Novolock Ltd Pipeline Products & Ongoing Clinical Trials Overview 144

5.60 Olympus Medical Systems Corp. Company Overview 145

5.60.1 Olympus Medical Systems Corp. Pipeline Products & Ongoing Clinical Trials Overview 145

5.61 Parker Hannifin Corporation Company Overview 146

5.61.1 Parker Hannifin Corporation Pipeline Products & Ongoing Clinical Trials Overview 146

5.62 Physcient, Inc. Company Overview 148

5.62.1 Physcient, Inc. Pipeline Products & Ongoing Clinical Trials Overview 148

5.63 POP Medical Solutions Company Overview 152

5.63.1 POP Medical Solutions Pipeline Products & Ongoing Clinical Trials Overview 152

5.64 Pro-Dex, Inc. Company Overview 155

5.64.1 Pro-Dex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 155

5.65 Queen Mary University of London Company Overview 158

5.65.1 Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 158

5.66 Ratner BioMedical Inc. Company Overview 159

5.66.1 Ratner BioMedical Inc. Pipeline Products & Ongoing Clinical Trials Overview 159

5.67 Resultados y Calidad del Sistema Sanitario Publico de Andalucia Company Overview 160

5.67.1 Resultados y Calidad del Sistema Sanitario Publico de Andalucia Pipeline Products & Ongoing Clinical Trials Overview 160

5.68 Sanovas, Inc. Company Overview 164

5.68.1 Sanovas, Inc. Pipeline Products & Ongoing Clinical Trials Overview 164

5.69 simedeq Company Overview 166

5.69.1 simedeq Pipeline Products & Ongoing Clinical Trials Overview 166

5.70 Simon Fraser University Company Overview 167

5.70.1 Simon Fraser University Pipeline Products & Ongoing Clinical Trials Overview 167

5.71 SRI International Company Overview 168

5.71.1 SRI International Pipeline Products & Ongoing Clinical Trials Overview 168

5.72 StatLink Surgical Company Overview 169

5.72.1 StatLink Surgical Pipeline Products & Ongoing Clinical Trials Overview 169

5.73 Stepwise Ltd Company Overview 170

5.73.1 Stepwise Ltd Pipeline Products & Ongoing Clinical Trials Overview 170

5.74 Surgical Energetics LLC Company Overview 171

5.74.1 Surgical Energetics LLC Pipeline Products & Ongoing Clinical Trials Overview 171

5.75 SurgyAid, LLC Company Overview 172

5.75.1 SurgyAid, LLC Pipeline Products & Ongoing Clinical Trials Overview 172

5.76 Synaptive Medical Inc. Company Overview 173

5.76.1 Synaptive Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 173

5.77 Teleflex Incorporated Company Overview 174

5.77.1 Teleflex Incorporated Pipeline Products & Ongoing Clinical Trials Overview 174

5.78 Tepha, Inc. Company Overview 176

5.78.1 Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview 176

5.79 TeVido BioDevices, LLC Company Overview 177

5.79.1 TeVido BioDevices, LLC Pipeline Products & Ongoing Clinical Trials Overview 177

5.80 The Feinstein Institute for Medical Research Company Overview 178

5.80.1 The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview 178

5.81 The Johns Hopkins University Company Overview 180

5.81.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 180

5.82 The University of Utah Company Overview 181

5.82.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 181

5.83 TransEnterix, Inc. Company Overview 182

5.83.1 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 182

5.84 Trinity College Dublin Company Overview 183

5.84.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 183

5.85 Univalue Valorizacion, S.L. Company Overview 184

5.85.1 Univalue Valorizacion, S.L. Pipeline Products & Ongoing Clinical Trials Overview 184

5.86 Universitat Politecnica de Catalunya Company Overview 185

5.86.1 Universitat Politecnica de Catalunya Pipeline Products & Ongoing Clinical Trials Overview 185

5.87 University of Florida Company Overview 187

5.87.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 187

5.88 University of Louisville Company Overview 188

5.88.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 188

5.89 University of Minnesota Company Overview 190

5.89.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview 190

5.90 University of New Mexico Company Overview 191

5.90.1 University of New Mexico Pipeline Products & Ongoing Clinical Trials Overview 191

5.91 University of North Carolina Company Overview 192

5.91.1 University of North Carolina Pipeline Products & Ongoing Clinical Trials Overview 192

5.92 University of South Florida Company Overview 193

5.92.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 193

5.93 University of Texas at Austin Company Overview 204

5.93.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 204

5.94 University of Texas Medical Branch at Galveston Company Overview 206

5.94.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 206

5.95 University of Virginia Company Overview 209

5.95.1 University of Virginia Pipeline Products & Ongoing Clinical Trials Overview 209

5.96 University of Washington Company Overview 210

5.96.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 210

5.97 University of Wisconsin Madison Company Overview 211

5.97.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 211

5.98 USGI Medical, Inc. Company Overview 213

5.98.1 USGI Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 213

5.99 Vanderbilt University Company Overview 217

5.99.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 217

5.100 Vascular Insights LLC Company Overview 223

5.100.1 Vascular Insights LLC Pipeline Products & Ongoing Clinical Trials Overview 223

5.101 Veol Medical Technologies Company Overview 224

5.101.1 Veol Medical Technologies Pipeline Products & Ongoing Clinical Trials Overview 224

5.102 W.O.M. World Of Medicine GmbH Company Overview 225

5.102.1 W.O.M. World Of Medicine GmbH Pipeline Products & Ongoing Clinical Trials Overview 225

5.103 Weill Cornell Medical College Company Overview 226

5.103.1 Weill Cornell Medical College Pipeline Products & Ongoing Clinical Trials Overview 226

6 Surgical Devices- Recent Developments 227

7 Appendix 362

7.1 Methodology 362

7.2 About GlobalData 364

7.3 Contact Us 365

7.4 Disclaimer 365

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Surgical Devices under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the products current stage of development, territory and estimated launch date

Source: http://www.researchbeam.com/surgical-devices-medical-devices-pipeline-assessment-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#surgical devices market #surgical devices #global surgical devices market #surgical devices market size #surgical devices market share #surgical devices market trends #surgical devices market forecast #surgical devices market futures #surgical devices market opportunities #surgical devices market news #surgical devices market strategy

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021

Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection methods in use for PC.

Enquiry about report: http://www.researchbeam.com/pancreatic-cancer-therapeutics-in-major-developed-to-2021-strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-landscape-market/enquire-about-report

Scope

Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.

- What factors are driving the market growth?

- How can the factors limiting growth be overcome in the future?

The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline are drugs inhibiting signal transduction.

- What are the dynamics of the remaining 49% of the pipeline?

- How does this reflect the need for novel targeted therapies?

Key mechanisms of action across the pipeline include cancer immunotherapies against IAP repeat containing proteins, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.

- What is the scientific rationale behind these targets?

Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, HyperAcute Pancreas, G17DT and clivatuzumab tetraxetan. However, their sales will be limited by their expected high costs.

- Where will these novel therapies fit into the current treatment algorithm for PC?

The pipeline therapies, G17DT is expected to have the strongest performance, with revenues of $141m by 2021.

- How will the other late stage pipeline drugs perform commercially

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 11

2.1 Disease Introduction 11

2.2 Epidemiology 11

2.3 Symptoms 12

2.4 Risk Factors 13

2.4.1 Age 13

2.4.2 Smoking 13

2.4.3 Obesity 13

2.4.4 Diet 13

2.4.5 Inherited Mutations 14

2.4.6 Chronic Pancreatitis 14

2.4.7 Diabetes 14

2.4.8 Infectious Diseases Risk Factors 14

2.4.9 Precursor Lesions 15

2.5 Pathophysiology 15

2.5.1 Somatic Mutations 15

2.6 Disease Stages 17

2.7 Diagnosis 18

2.8 Disease Prognosis 19

2.9 Treatment Algorithm 19

2.9.1 Adjuvant Therapy, Resected Cancer 20

2.9.2 First-Line Treatment, Unresectable 21

2.9.3 Second-Line Treatment, Unresectable 22

3 Commercial and Clinical Prospects of Marketed Products 24

3.1 Approved Products 24

3.1.1 Gemcitabine 24

3.1.2 IV Fluorouracil 25

3.1.3 Abraxane 26

3.1.4 Tarceva 27

3.1.5 Teysuno/TS-1/S-1 28

3.1.6 Onivyde 29

3.2 Off-Label Products 30

3.2.1 Capecitabine 30

3.2.2 Oxaliplatin 30

3.3 Marketed Products - Discussion 31

4 Pipeline for Pancreatic Cancer Therapeutics 36

4.1 Overview by Phase and Molecule Type 37

4.2 Overview by Molecular Target 38

4.3 Clinical Trials 42

4.3.1 Clinical Trial Failure Rates 42

4.3.2 Clinical Trial Duration 46

4.3.3 Clinical Trial Size 50

4.3.4 Discussion 55

4.4 Promising Pipeline Molecules 55

4.4.1 Evofosfamide (TH-302) - Threshold Pharmaceuticals. 55

4.4.2 Tertomotide - Kael-GemVax 58

4.4.3 Ruxolitinib phosphate - Incyte Corporation 59

4.4.4 HyperAcute Pancreas/ Algenpantucel-L - NewLink Genetics Corporation 61

4.4.5 G17DT - Cancer Advances 64

4.4.6 Nimotuzumab - InnoMab 65

4.4.7 Clivatuzumab Tetraxetan - Immunomedics. 66

4.5 Pipeline Discussion 68

5 Market Forecast to 2021 72

5.1 Global Market 73

5.2 North America 74

5.2.1 US 74

5.2.2 Canada 77

5.3 Top Five European Markets 80

5.3.1 Treatment Usage Patterns 80

5.3.2 Annual Cost of Treatment 81

5.3.3 Market Size 82

5.3.4 Japan 84

6 Drivers and Barriers 87

6.1 Drivers 87

6.1.1 Rising prevalence across all target markets 87

6.1.2 Orphan Indication Incentives 87

6.1.3 Growing Disease Awareness 88

6.1.4 Better Diagnostics 88

6.1.5 All Treatment Segments Have an Unmet Need 88

6.1.6 High Number of Candidates in Late-Stage Drug Development 88

6.2 Barriers 89

6.2.1 Generics Will Restrict Premium Pricing 89

6.2.2 High Failure Rates 89

6.2.3 The High Genetic Heterogeneity of PC 89

6.2.4 Typical Late Stage of Diagnosis 89

7 Strategic Consolidations 91

7.1 Major Co-Development Deals 91

7.1.1 Merck Serono Enters into Co-development Agreement with Threshold Pharma for TH-302 93

7.1.2 GSK Enters into Co-development Agreement with OncoMed Pharmaceuticals for Novel Antibody Therapeutics 94

7.1.3 OncoMed Pharma Enters into Co-development Agreement with Celgene Corporation for Anti-Cancer Stem Cell Therapies 94

7.2 Major Licensing Deals 95

7.2.1 Baxter International Enters into a Licensing Agreement with Onconova Therapeutics for Rigosertib 97

7.2.2 Janssen Biotech Enters into Worldwide Licensing Agreement with Pharmacyclics for PCI-32765 98

7.2.3 AVEO Pharmaceuticals Enters into a License and Development Agreement with Schering-Plough Corporation for AV-299 98

7.2.4 Ardea Biosciences Enters Into a Licensing Agreement with Bayer HealthCare to Develop MEK Inhibitors 99

8 Appendix 100

8.1 All Pipeline Drugs by Phase 100

8.1.1 Discovery 100

8.1.2 Preclinical 103

8.1.3 Phase I 106

8.1.4 Phase II 109

8.1.5 Phase III 113

8.1.6 Pre-Registration 114

8.2 Market Forecasts to 2020 114

8.2.1 Global 114

8.2.2 The US 115

8.2.3 Canada 115

8.2.4 The UK 116

8.2.5 France 116

8.2.6 Germany 116

8.2.7 Italy 117

8.2.8 Spain 117

8.2.9 Japan 117

8.3 References 118

8.4 Abbreviations 132

8.5 Methodology 134

8.6 Coverage 134

8.7 Secondary Research 135

8.8 Therapeutic Landscape 135

8.9 Epidemiology-Based Forecasting 135

8.9.1 Analogous Forecasting Methodology 136

8.10 Market Size by Geography 136

8.10.1 Forecasting Model for Therapeutic Areas 137

8.11 Geographical Landscape 137

8.12 Pipeline Analysis 137

8.13 Competitive Landscape 138

8.14 Contact Us 138

8.15 Disclaimer 138

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.

- Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting the current unmet needs and how they can be addressed to allow a competitive understanding of gaps in the current market.

- Analyze the pancreatic cancer pipeline and stratify by stage of development, molecule type, and molecular target.

- Visualize the clinical safety and efficacy of late-stage pipeline drugs via a detailed heat map, outlining the results across major clinical trial endpoints.

- Understand the growth in patient epidemiology, annual therapy costs, and market revenues for the pancreatic cancer market globally and across the US, UK, France, Germany, Italy, Spain, Japan, and Canada.

- Identify commercial opportunities in the pancreatic cancer deals landscape by analyzing trends in licensing and co-development deals.

Source: http://www.researchbeam.com/pancreatic-cancer-therapeutics-in-major-developed-to-2021-strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-landscape-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn:

http://www.linkedin.com/company/research-beam

Global Power Transformers Market, Update 2015

Power Transformers Market, Update 2015 Global Market Size, Equipment Market Share and Key Country Analysis to 2020 is the latest market analysis report, the industry analysis specialists that offer comprehensive information and understanding of the power industry.

Enquiry about report: http://www.researchbeam.com/power-transformers-update-2015-global-size-equipment-share-and-key-country-analysis-to-2020-market/enquire-about-report

The report gives detailed information on the current power transformer market, focusing on key countries, as well as covering the global scenario. The report analyzes the revenues, average price and volume by power transformers used by various voltage line segments for the key nine countries in the market. The market shares for the key players in each country have been provided. At global level, the drivers and restraints of the market is also provided. The report is built using data and information sourced from primary and secondary research and in-house analysis by team of industry experts.

Scope

The report analyses global power transformers market. Its scope includes

An in-depth analysis of the power transformer market in China, US, India, Saudi Arabia, Brazil, Japan, Germany, Canada and UK.

It covers average price, volume (in terms of MVA) and market size for the period from 2006 to 2020 for power transformers.

Market share of players/leading players for power transformers in 2014 is provided.

It discusses the key drivers and restraints impacting the global power transformer market.

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 10

2 Introduction 14

2.1 Power Transformers, Overview 14

2.2 GlobalData Report Guidance 14

3 Power Transformers Market, Global 16

3.1 Power Transformers Market, Global, Overview 16

3.2 Power Transformers Market, Global, Volume, 2007-2020 16

3.3 Power Transformers Market, Global, Revenue Analysis, 2007-2020 18

3.4 Power Transformers Market, Global, Share by Market Revenue, 2014 20

3.5 Power Transformers Market, Global, Drivers 22

3.5.1 Growing Electricity Demand 22

3.5.2 Replacement Market to Drive Power Transformer Demand in North America and Europe 23

3.5.3 Thriving Economies in the Asia-Pacific, Eastern Europe and Middle East Regions to Drive Demand for New Power Transformers 24

3.5.4 Strengthening of the Electricity Grid 25

3.5.5 Changing Nature of Power Generation 25

3.6 Power Transformers Market, Global, Restraints 26

3.6.1 Pricing Pressures 26

3.6.2 Local Competition as Entry Barrier 27

3.6.3 Increasing Prices of Raw Materials 27

3.6.4 Global Financial Crisis and Economic Slowdown of Major Markets 28

4 Power Transformers Market, Global, Key Country Analysis 29

4.1 Power Transformers Market, China 29

4.1.1 Power Transformers Market, China, Overview 29

4.1.2 Power Transformers Market, China, Volume, 2007-2020 29

4.1.3 Power Transformers Market, China, Average Price by Voltage Level, 2007?2020 34

4.1.4 Power Transformers Market, China, Revenue Analysis, 2007-2020 36

4.1.5 Power Transformers Market, China, Market Share by Revenue, 2014 41

4.1.6 Power Transformers Market, China, Regulations 43

4.2 Power Transformers Market, US 47

4.2.1 Power Transformers Market, US, Overview 47

4.2.2 Power Transformers Market, US, Volume, 2007-2020 47

4.2.3 Power Transformers Market, US, Average Price by Voltage Level, 2007?2020 52

4.2.4 Power Transformers Market, US, Revenue Analysis, 2007-2020 54

4.2.5 Power Transformers Market, US, Market Share by Revenue, 2014 59

4.2.6 Power Transformers Market, US, Regulations 61

4.3 Power Transformers Market, India 64

4.3.1 Power Transformers Market, India, Overview 64

4.3.2 Power Transformers Market, India, Volume, 2007-2020 65

4.3.3 Power Transformers Market, India, Average Price by Voltage Level, 2007?2020 70

4.3.4 Power Transformers Market, India, Revenue Analysis, 2007-2020 72

4.3.5 Power Transformers Market, India, Market Share by Revenue, 2014 77

4.3.6 Power Transformers Market, India, Regulations 79

4.4 Power Transformers Market, Saudi Arabia 81

4.4.1 Power Transformers Market, Saudi Arabia, Overview 81

4.4.2 Power Transformers Market, Saudi Arabia, Volume, 2007-2020 82

4.4.3 Power Transformers Market, Saudi Arabia, Average Price by Voltage Level, 2007?2020 87

4.4.4 Power Transformers Market, Saudi Arabia, Revenue Analysis, 2007-2020 89

4.4.5 Power Transformers Market, Saudi Arabia, Market Share by Revenue, 2014 94

4.4.6 Power Transformers Market, Saudi Arabia, Regulations 96

4.5 Power Transformers Market, Brazil 97

4.5.1 Power Transformers Market, Brazil, Overview 97

4.5.2 Power Transformers Market, Brazil, Volume, 2007-2020 98

4.5.3 Power Transformers Market, Brazil, Average Price by Voltage Level, 2007?2020 103

4.5.4 Power Transformers Market, Brazil, Revenue Analysis, 2007-2020 105

4.5.5 Power Transformers Market, Brazil, Market Share by Revenue, 2014 110

4.5.6 Power Transformers Market, Brazil, Regulations 112

4.6 Power Transformers Market, Japan 115

4.6.1 Power Transformers Market, Japan, Overview 115

4.6.2 Power Transformers Market, Japan, Volume, 2007-2020 116

4.6.3 Power Transformers Market, Japan, Average Price by Voltage Level, 2007?2020 120

4.6.4 Power Transformers Market, Japan, Revenue Analysis, 2007-2020 122

4.6.5 Power Transformers Market, Japan, Market Share by Revenue, 2014 127

4.6.6 Power Transformers Market, Japan, Regulations 129

4.7 Power Transformers Market, Germany 132

4.7.1 Power Transformers Market, Germany, Overview 132

4.7.2 Power Transformers Market, Germany, Volume, 2007-2020 132

4.7.3 Power Transformers Market, Germany, Average Price by Voltage Level, 2007?2020 137

4.7.4 Power Transformers Market, Germany, Revenue Analysis, 2007-2020 139

4.7.5 Power Transformers Market, Germany, Market Share by Revenue, 2014 144

4.7.6 Power Transformers Market, Germany, Regulations 146

4.8 Power Transformers Market, Canada 150

4.8.1 Power Transformers Market, Canada, Overview 150

4.8.2 Power Transformers Market, Canada, Volume, 2007?2020 150

4.8.3 Power Transformers Market, Canada, Average Price by Voltage Level, 2007?2020 155

4.8.4 Power Transformers Market, Canada, Revenue Analysis, 2007?2020 157

4.8.5 Power Transformers Market, Canada, Market Share by Revenue, 2014 162

4.8.6 Power Transformers Market, Canada, Regulations 164

4.9 Power Transformers Market, UK 165

4.9.1 Power Transformers Market, UK, Overview 165

4.9.2 Power Transformers Market, UK, Volume, 2007-2020 166

4.9.3 Power Transformers Market, UK, Average Price, 2007?2020 171

4.9.4 Power Transformers Market, UK, Revenue Analysis, 2007-2020 173

4.9.5 Power Transformers Market, UK, Market Share by Revenue, 2014 178

4.9.6 Power Transformers Market, UK, Regulations 180

5 Appendix 183

5.1 Definitions 183

5.1.1 Power 183

5.1.2 Installed Capacity 183

5.1.3 Electricity Generation 183

5.1.4 Electricity Consumption 183

5.1.5 Thermal Power Plant 183

5.1.6 Hydropower Plant 183

5.1.7 Nuclear Power 183

5.1.8 Renewable Energy Resources 184

5.1.9 Power Transformer 184

5.2 Abbreviations 184

5.3 Bibliography 186

5.4 Research Methodology 188

5.4.1 Coverage 189

5.4.2 Secondary Research 189

5.4.3 Primary Research 190

5.5 Disclaimer 190

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to

Facilitate decision making, by providing historical and forecast data on the revenue and volume for power transformers market

Develop strategies based on the various market developments in the power transformers market

Identify key partners and business development avenues, based on an understanding of the market movements of the major competitors in the power transformers market.

Respond to your competitors business structure, strategy and prospects.

Source: http://www.researchbeam.com/power-transformers-update-2015-global-size-equipment-share-and-key-country-analysis-to-2020-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Complex Partial Seizure Global Clinical Trials Review, H2, 2015

Complex Partial Seizure Global Clinical Trials Review, H2, 2015 provides an overview of Complex Partial Seizure clinical trials scenario. This report provides top line data relating to the clinical trials on Complex Partial Seizure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Enquiry about report: http://www.researchbeam.com/complex-partial-seizure-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Complex Partial Seizure to Central Nervous System Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Complex Partial Seizure to Central Nervous System Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Complex Partial Seizure Therapeutics Clinical Trials 28

Prominent Drugs 30

Clinical Trial Profile Snapshots 31

Appendix 53

Abbreviations 53

Definitions 53

Research Methodology 54

Secondary Research 54

About GlobalData 55

Disclaimer 55

Source 56

Source: http://www.researchbeam.com/complex-partial-seizure-global-clinical-trials-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#complex partial seizures #complex partial seizures market #complex partial seizures market size #complex partial seizures market share #complex partial seizures market trends #complex partial seizures market forecast

Polyethylene Terephthalate (PET) Industry Outlook in the US to 2019

Polyethylene Terephthalate (PET) Industry Outlook in the US to 2019 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants, provides in-depth coverage of the USs PET industry and presents major market trends. The report covers the USs PET plants and presents installed capacity by production process and technology.

Enquiry about report: http://www.researchbeam.com/polyethylene-terephthalate-pet-industry-outlook-in-the-us-to-2019-size-company-share-price-trends-capacity-forecasts-of-all-active-and-planned-plants-market/enquire-about-report

Scope

- PET industry supply scenario in the US from 2005 to 2019, comprising plant capacity growth and installed plant capacity by production process and technology

- Detailed information of all active plants and planned PET projects in the US with capacity forecasts to 2019 and additional details such as production process, technology operator and equity

- PET industry market dynamics in the US from 2005 to 2019, consisting of market size, demand and production outlook, demand by end-use sector, and average prices

- Trade balance data from 2005 to 2019, including import and export data and net exports and imports as a percentage of demand

- Company snapshots, including company overview, business description and information on current and upcoming PET plants

- Company capacity shares for key PET producers

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

The US Polyethylene Terephthalate (PET) Industry, Supply Scenario, 2005-2019 6

The US Polyethylene Terephthalate (PET) Industry, Total Plant Capacity, 2005-2019 6

The US Polyethylene Terephthalate (PET), Industry, Installed Plant Capacity by Production Process, 2014 15

The US Polyethylene Terephthalate (PET) Industry, Installed Plant Capacity by Technology, 2014 17

The US Polyethylene Terephthalate (PET) Industry, Company Share, 2014 20

The US, Polyethylene Terephthalate (PET) Industry, Planned Projects Details, 2015-2019 21

The US Polyethylene Terephthalate (PET) Industry, Market Dynamics, 2005-2019 22

The US Polyethylene Terephthalate (PET) Industry, Market Size, 2005-2019 22

The US Polyethylene Terephthalate (PET), Demand and Production Outlook, 2005-2019 24

The US Polyethylene Terephthalate (PET) Industry, Demand by End Use Sector, 2014 26

The US, Polyethylene Terephthalate (PET) Industry, Price Forecasts, 2005-2019 27

The US Polyethylene Terephthalate (PET), Trade Balance, 2005-2019 29

The US Polyethylene Terephthalate (PET) Industry, Imports and Exports, 2005-2019 29

The US Polyethylene Terephthalate (PET) Industry, Net Exports, 2005-2019 31

The US Polyethylene Terephthalate (PET) Industry, Imports as Percentage of Demand, 2005-2019 33

Alfa, S.A.B. de C.V., Company Snapshot 35

Alfa, S.A.B. de C.V., Company Overview 35

Alfa, S.A.B. de C.V., Key Information 35

Alfa, S.A.B. de C.V., Business Description 35

Business Overview 35

Alfa, S.A.B. de C.V., Polyethylene Terephthalate (PET) Market, 2014 37

Alfa, S.A.B. de C.V., Polyethylene Terephthalate (PET) Capacity Split, the US and Rest of the World, 2014 37

Alfa, S.A.B. de C.V., Polyethylene Terephthalate (PET) Plant Capacity Share in the US, 2014 38

Alfa, S.A.B. de C.V., Polyethylene Terephthalate (PET) Capacity in the US, 2005-2019 39

Alfa, S.A.B. de C.V., Polyethylene Terephthalate (PET) Plant Details in the US, 2014 40

SWOT Analysis 41

Overview 41

Alfa, S.A.B. de C.V. Strengths 41

Alfa, S.A.B. de C.V. Weaknesses 42

Alfa, S.A.B. de C.V. Opportunities 42

Alfa, S.A.B. de C.V. Threats 43

Indorama Ventures PCL, Company Snapshot 45

Indorama Ventures PCL, Company Overview 45

Indorama Ventures PCL, Key Information 45

Indorama Ventures PCL, Polyethylene Terephthalate (PET) Market, 2014 46

Indorama Ventures PCL, Polyethylene Terephthalate (PET) Capacity Split, the US and Rest of the World, 2014 46

Indorama Ventures PCL, Polyethylene Terephthalate (PET) Plant Capacity Share in the US, 2014 47

Indorama Ventures PCL, Polyethylene Terephthalate (PET) Capacity in the US, 2005-2019 48

Indorama Ventures PCL, Polyethylene Terephthalate (PET) Plant Details in the US, 2014 48

Formosa Plastics Group, Company Snapshot 49

Formosa Plastics Group, Company Overview 49

Formosa Plastics Group, Key Information 49

Formosa Plastics Group, Business Description 49

Business Overview 49

Formosa Plastics Group, Polyethylene Terephthalate (PET) Market, 2014 51

Formosa Plastics Group, Polyethylene Terephthalate (PET) Capacity Split, the US and Rest of the World, 2014 51

Formosa Plastics Group, Polyethylene Terephthalate (PET) Plant Capacity Share in the US, 2014 52

Formosa Plastics Group, Polyethylene Terephthalate (PET) Capacity in the US, 2005-2019 53

Formosa Plastics Group, Polyethylene Terephthalate (PET) Plant Details in the US, 2014 53

SWOT Analysis 54

Overview 54

Formosa Plastics Group Strengths 54

Formosa Plastics Group Weaknesses 55

Formosa Plastics Group Opportunities 55

Formosa Plastics Group Threats 56

Appendix 58

Definitions 58

Installed Plant Capacity 58

Process 58

Technology 58

Abbreviations 58

GlobalDatas Methodology 58

Coverage 58

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Disclaimer 60

Source: http://www.researchbeam.com/polyethylene-terephthalate-pet-industry-outlook-in-the-us-to-2019-size-company-share-price-trends-capacity-forecasts-of-all-active-and-planned-plants-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Sarcopenia - Pipeline Review, H2 2015

‘Sarcopenia - Pipeline Review, H2 2015’, provides an overview of the Sarcopenia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

Enquiry about report: http://www.researchbeam.com/sarcopenia-pipeline-review-h2-2015-market/enquire-about-report

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Sarcopenia and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Sarcopenia pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sarcopenia Overview 7

Therapeutics Development 8

Pipeline Products for Sarcopenia - Overview 8

Pipeline Products for Sarcopenia - Comparative Analysis 9

Sarcopenia - Therapeutics under Development by Companies 10

Sarcopenia - Therapeutics under Investigation by Universities/Institutes 11

Sarcopenia - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Sarcopenia - Products under Development by Companies 14

Sarcopenia - Products under Investigation by Universities/Institutes 15

Sarcopenia - Companies Involved in Therapeutics Development 16

GlaxoSmithKline Plc 16

Myos Corporation 17

Neurotune AG 18

Novartis AG 19

PolyNovo Limited 20

PsiOxus Therapeutics Limited 21

Regeneron Pharmaceuticals, Inc. 22

Sumitomo Dainippon Pharma Co., Ltd. 23

Sarcopenia - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AOD-9604 - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ARM-210 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

bimagrumab - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

BIO-101 - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

BIO-103 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Espindolol - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NEP-28 - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

NT-1654 - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Proteins for Musculoskeletal Disorders - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Recombinant Protein for Sarcopenia - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

S-107 - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

trevogrumab - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Sarcopenia - Recent Pipeline Updates 50

Sarcopenia - Dormant Projects 54

Sarcopenia - Discontinued Products 55

Sarcopenia - Product Development Milestones 56

Featured News & Press Releases 56

Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 56

Dec 14, 2011: Calzada Announces New Applications For AOD9604 56

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 57

Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 58

Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Disclaimer 62

Source: http://www.researchbeam.com/sarcopenia-pipeline-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#sarcopenia market demands #sarcopenia market outlook #sarcopenia market overview #sarcopenia market developments #sarcopenia market technology #sarcopenia market segmentation #sarcopenia market application #sarcopenia market strategy #sarcopenia market opportunities #sarcopenia market research #sarcopenia market news #sarcopenia market analysis #sarcopenia market growth #sarcopenia market futures

Human Papillomavirus Infections - Pipeline Review, H2 2015

Human Papillomavirus Infections - Pipeline Review, H2 2015, provides an overview of the Human Papillomavirus Infectionss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Enquiry about report: http://www.researchbeam.com/human-papillomavirus-infections-pipeline-review-h2-2015-market/enquire-about-report

List of Tables

Number of Products under Development for Human Papillomavirus Infections, H2 2015 13

Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 17

Comparative Analysis by Late Stage Development, H2 2015 18

Comparative Analysis by Clinical Stage Development, H2 2015 19

Comparative Analysis by Early Stage Development, H2 2015 20

Comparative Analysis by Unknown Stage Development, H2 2015 21

Products under Development by Companies, H2 2015 22

Products under Development by Companies, H2 2015 (Contd..1) 23

Products under Development by Companies, H2 2015 (Contd..2) 24

Products under Development by Companies, H2 2015 (Contd..3) 25

Products under Investigation by Universities/Institutes, H2 2015 26

Human Papillomavirus Infections - Pipeline by 3M Drug Delivery Systems, H2 2015 27

Human Papillomavirus Infections - Pipeline by Admedus Ltd, H2 2015 28

Human Papillomavirus Infections - Pipeline by Agilvax, Inc., H2 2015 29

Human Papillomavirus Infections - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 30

Human Papillomavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 31

Human Papillomavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2015 32

Human Papillomavirus Infections - Pipeline by Biogenomics Limited, H2 2015 33

Human Papillomavirus Infections - Pipeline by BioMAS Ltd., H2 2015 34

Human Papillomavirus Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2015 35

Human Papillomavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 36

Human Papillomavirus Infections - Pipeline by Crucell N.V., H2 2015 37

Human Papillomavirus Infections - Pipeline by EpiPharm AG, H2 2015 38

Human Papillomavirus Infections - Pipeline by FluGen, Inc., H2 2015 39

Human Papillomavirus Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 40

Human Papillomavirus Infections - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 41

Human Papillomavirus Infections - Pipeline by Genticel S.A., H2 2015 42

Human Papillomavirus Infections - Pipeline by Helix BioPharma Corp., H2 2015 43

Human Papillomavirus Infections - Pipeline by Immunservice GmbH, H2 2015 44

Human Papillomavirus Infections - Pipeline by Indian Immunologicals Limited, H2 2015 45

Human Papillomavirus Infections - Pipeline by Kaketsuken K.K., H2 2015 46

Human Papillomavirus Infections - Pipeline by LEO Pharma A/S, H2 2015 47

Human Papillomavirus Infections - Pipeline by MediGene AG, H2 2015 48

Human Papillomavirus Infections - Pipeline by NanoViricides, Inc., H2 2015 49

Human Papillomavirus Infections - Pipeline by Nielsen Biosciences, Inc., H2 2015 50

Human Papillomavirus Infections - Pipeline by Novan, Inc., H2 2015 51

Human Papillomavirus Infections - Pipeline by Novartis AG, H2 2015 52

Human Papillomavirus Infections - Pipeline by Organic Vaccines, H2 2015 53

Human Papillomavirus Infections - Pipeline by Promius Pharma, LLC, H2 2015 54

Human Papillomavirus Infections - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 55

Human Papillomavirus Infections - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 56

Human Papillomavirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015 57

Human Papillomavirus Infections - Pipeline by Spider Biotech, H2 2015 58

Human Papillomavirus Infections - Pipeline by Starpharma Holdings Limited, H2 2015 59

Human Papillomavirus Infections - Pipeline by Tamir Biotechnology, Inc., H2 2015 60

Human Papillomavirus Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 61

Assessment by Monotherapy Products, H2 2015 62

Assessment by Combination Products, H2 2015 63

Number of Products by Stage and Target, H2 2015 65

Number of Products by Stage and Mechanism of Action, H2 2015 67

Number of Products by Stage and Route of Administration, H2 2015 69

Number of Products by Stage and Molecule Type, H2 2015 71

Human Papillomavirus Infections Therapeutics - Recent Pipeline Updates, H2 2015 140

Human Papillomavirus Infections - Dormant Projects, H2 2015 152

Human Papillomavirus Infections - Dormant Projects (Contd..1), H2 2015 153

Human Papillomavirus Infections - Dormant Projects (Contd..2), H2 2015 154

Human Papillomavirus Infections - Dormant Projects (Contd..3), H2 2015 155

Human Papillomavirus Infections - Discontinued Products, H2 2015 156

List of Figures

Number of Products under Development for Human Papillomavirus Infections, H2 2015 13

Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 19

Comparative Analysis by Early Stage Products, H2 2015 20

Assessment by Monotherapy Products, H2 2015 62

Number of Products by Top 10 Targets, H2 2015 64

Number of Products by Stage and Top 10 Targets, H2 2015 64

Number of Products by Top 10 Mechanism of Actions, H2 2015 66

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 66

Number of Products by Top 10 Routes of Administration, H2 2015 68

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 68

Number of Products by Top 10 Molecule Types, H2 2015 70

Number of Products by Stage and Top 10 Molecule Types, H2 2015 70

Source: http://www.researchbeam.com/human-papillomavirus-infections-pipeline-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#human papillomavirus infections market demands #human papillomavirus infections market outlook #human papillomavirus infections market overview

Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015

Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015 provides an overview of Polycystic Kidney Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Kidney Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7) , phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials) .

Enquiry about report: http://www.researchbeam.com/polycystic-kidney-disease-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7) , Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table Of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Polycystic Kidney Disease 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Polycystic Kidney Disease to Genito Urinary System And Sex Hormones Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Polycystic Kidney Disease to Genito Urinary System And Sex Hormones Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Polycystic Kidney Disease 25

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials 30

Prominent Drugs 31

Clinical Trial Profiles 32

Clinical Trial Overview of Top Companies 32

Otsuka Holdings Co., Ltd. 32

Clinical Trial Overview of Otsuka Holdings Co., Ltd. 32

Pfizer Inc. 34

Clinical Trial Overview of Pfizer Inc. 34

Ipsen S.A. 35

Clinical Trial Overview of Ipsen S.A. 35

Novartis AG 36

Clinical Trial Overview of Novartis AG 36

Kadmon Corporation, LLC 37

Clinical Trial Overview of Kadmon Corporation, LLC 37

Merck & Co., Inc. 38

Clinical Trial Overview of Merck & Co., Inc. 38

Daiichi Sankyo Company, Limited 39

Clinical Trial Overview of Daiichi Sankyo Company, Limited 39

Diablo Clinical Research, Inc. 40

Clinical Trial Overview of Diablo Clinical Research, Inc. 40

C. H. Boehringer Sohn AG & Co. KG 41

Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 41

Boehringer Ingelheim Pharmaceuticals, Inc. 42

Clinical Trial Overview of Boehringer Ingelheim Pharmaceuticals, Inc. 42

Clinical Trial Overview of Top Institutes / Government 43

Kyorin University 43

Clinical Trial Overview of Kyorin University 43

Federico II University 44

Clinical Trial Overview of Federico II University 44

Mario Negri Institute for Pharmacological Research 45

Clinical Trial Overview of Mario Negri Institute for Pharmacological Research 45

Mayo Clinic 46

Clinical Trial Overview of Mayo Clinic 46

Shanghai Changzheng Hospital 47

Clinical Trial Overview of Shanghai Changzheng Hospital 47

The National Institute of Diabetes and Digestive and Kidney Diseases 48

Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 48

Toranomon Hospital 49

Clinical Trial Overview of Toranomon Hospital 49

Addenbrooke's Hospital 50

Clinical Trial Overview of Addenbrooke's Hospital 50

Assistance Publique - Hopitaux de Paris 51

Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 51

Azienda Ospedaliera Ospedale Policlinico Consorziale 52

Clinical Trial Overview of Azienda Ospedaliera Ospedale Policlinico Consorziale 52

Five Key Clinical Profiles 53

Appendix 90

Abbreviations 90

Definitions 90

Research Methodology 91

Secondary Research 91

About GlobalData 92

Disclaimer 92

Source 93

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Source: http://www.researchbeam.com/polycystic-kidney-disease-global-clinical-trials-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Down Syndrome Global Clinical Trials Review, H2, 2015

Down Syndrome Global Clinical Trials Review, H2, 2015 provides an overview of Down Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7) , phase, trial status, end points status and sponsor type.

Enquiry about report: http://www.researchbeam.com/down-syndrome-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7) , Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Middle East and Africa 12

Top Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Down Syndrome to Genetic Disorders Clinical Trials 14

Clinical Trials by Phase in G7 Countries 15

Clinical Trials in G7 Countries by Trial Status 16

Clinical Trials by E7 Countries: Proportion of Down Syndrome to Genetic Disorders Clinical Trials 17

Clinical Trials by Phase in E7 Countries 18

Clinical Trials in E7 Countries by Trial Status 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Subjects Recruited Over a Period of Time 24

Clinical Trials by Sponsor Type 25

Prominent Sponsors 26

Top Companies Participating in Down Syndrome Therapeutics Clinical Trials 27

Prominent Drugs 28

Clinical Trial Profile Snapshots 29

Appendix 65

Abbreviations 65

Definitions 65

Research Methodology 66

Secondary Research 66

About GlobalData 67

Disclaimer 67

Source 68

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Source: http://www.researchbeam.com/down-syndrome-global-clinical-trials-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#down syndrome market developments #down syndrome market research #down syndrome market overview #down syndrome market news #down syndrome market application #down syndrome market segmentation #down syndrome market strategy #down syndrome market futures #down syndrome market forecast #down syndrome market trends #down syndrome market share #down syndrome market size #down syndrome market #down syndrome

Hormone Deficiency Disorders Global Clinical Trials Review, H2, 2015

Hormone Deficiency Disorders Global Clinical Trials Review, H2, 2015" provides an overview of Hormone Deficiency Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Deficiency Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Enquiry about report: http://www.researchbeam.com/hormone-deficiency-disorders-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table Of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Report Guidance 4

Clinical Trials by Region 5

Clinical Trials and Average Enrollment by Country 6

Top Countries Contributing to Clinical Trials in Asia-Pacific 8

Top Five Countries Contributing to Clinical Trials in Europe 9

Top Countries Contributing to Clinical Trials in North America 10

Top Countries Contributing to Clinical Trials in Middle East and Africa 11

Clinical Trials by G7 Countries: Proportion of Hormone Deficiency Disorders to Hormonal Disorders Clinical Trials 12

Clinical Trials by Phase in G7 Countries 13

Clinical Trials in G7 Countries by Trial Status 14

Clinical Trials by Phase 15

In Progress Trials by Phase 16

Clinical Trials by Trial Status 17

Clinical Trials by End Point Status 18

Subjects Recruited Over a Period of Time 19

Clinical Trials by Sponsor Type 20

Prominent Sponsors 21

Top Companies Participating in Hormone Deficiency Disorders Therapeutics Clinical Trials 22

Prominent Drugs 23

Clinical Trial Profile Snapshots 24

Appendix 40

Abbreviations 40

Definitions 40

Research Methodology 41

Secondary Research 41

About GlobalData 42

Disclaimer 42

Source 43

Source: http://www.researchbeam.com/hormone-deficiency-disorders-global-clinical-trials-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Wind Power in Japan, Market Outlook to 2025, Update 2015 - Capacity, Generation, Levelized Cost of Energy (LCOE) , Investment Trends, Regulations and Company Profiles

Wind Power in Japan, Market Outlook to 2025, Update 2015 Capacity, Generation, Levelized Cost of Energy (LCOE) , Investment Trends, Regulations and Company Profiles is the latest report, the industry analysis specialists that offer comprehensive information and understanding of the wind power market in Japan.

Enquiry about report: http://www.researchbeam.com/wind-power-in-japan-outlook-to-2025-update-2015-capacity-generation-levelized-cost-of-energy-lcoe-investment-trends-regulations-and-company-profiles-market/enquire-about-report

The report provides in depth analysis on global renewable power market and global wind power market with forecasts up to 2025. The report analyzes the power market scenario in Japan (includes conventional thermal, nuclear, large hydro and renewable energy sources) and provides future outlook with forecasts up to 2025. The research details renewable power market outlook in the country (includes wind, small hydro, biopower and solar PV) and provides forecasts up to 2025. The report highlights installed capacity and power generation trends from 2001 to 2025 in Japan wind power market. A detailed coverage of renewable energy policy framework governing the market with specific policies pertaining to wind power is provided in the report. The research also provides company snapshots of some of the major market participants.

Table of Content:

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Executive Summary 8

2.1 Government Support in Conjunction with Technology Development Driving Global Renewable Power Installations 8

2.2 Top 10 Countries Account for Over 84% of Wind Power Capacity 8

3 Introduction 11

3.1 Carbon Emissions, Global, 2001-2014 11

3.2 Primary Energy Consumption, Global, 2001-2025 14

4 Renewable Power Market, Global, 2001 - 2025 19

4.1 Renewable Power Market, Global, Overview 19

4.2 Renewable Power Market, Global, Installed Capacity, 2001-2025 20

5 Wind Power Market, Global, 2001-2025 32

5.1 Wind Power Market, Global, Overview 32

5.2 Wind Power Market, Global, Installed Capacity, 2001-2025 32

6 Power Market, Japan, 2001-2025 47

6.1 Power Market, Japan, Overview 47

6.2 Power Market, Japan, Installed Capacity, 2001-2025 48

7 Renewable Power Market, Japan, 2001-2025 54

7.1 Renewable Power Market, Japan, Overview 54

7.2 Renewable Power Market, Japan, Installed Capacity, 2001-2025 55

8 Wind Power Market, Japan 62

8.1 Wind Power Market, Japan, Overview 62

8.2 Wind Power Market, Japan, Installed Capacity, 2001 - 2025 63

9 Power Market, Japan, Regulatory Scenario 75

9.1 Power Market, Japan, Reforms 75

9.2 Nuclear Power Policy 76

10 Wind Power Market, Japan, Company Profiles 80

10.1 Company Snapshot: Kyushu Electric Power Co., Inc. 80

10.2 Company Snapshot: Japan Wind Development Co., Ltd. 86

11 Appendix 103

11.1 Market Definitions 103

11.2 Abbreviations 104

Source: http://www.researchbeam.com/wind-power-in-japan-outlook-to-2025-update-2015-capacity-generation-levelized-cost-of-energy-lcoe-investment-trends-regulations-and-company-profiles-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#wind power market research #wind power market futures #wind power market overview #wind power market news #wind power market segmentation #wind power market application #wind power market analysis #wind power market growth #wind power market forecast #wind power market trends #wind power market share #wind power market size #wind power market #global wind power market #japanese wind turbine #japanese wind power market #wind power

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Enquiry about report: http://www.researchbeam.com/clostridium-difficile-infections-clostridium-difficile-associated-disease-global-clinical-trials-review-h2-2015-market/enquire-about-report

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Table of Content

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) to Infectious Disease Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Clinical Trials 28

Prominent Drugs 29

Latest Clinical Trials News on Clostridium Difficile Infections (Clostridium Difficile Associated Disease) 30

Sep 28, 2015: Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial 30

Sep 21, 2015: Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics in a Humanized Pig Model 30

Sep 20, 2015: Pivotal Phase 3 Studies of Bezlotoxumab, Merck™s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint 31

Sep 18, 2015: Summit Therapeutics Presents New Positive Preclinical Data on Novel C. difficile Antibiotic SMT19969 at ICAAC 2015 32

Sep 10, 2015: Summit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection 33

Jul 28, 2015: Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study 33

Jul 21, 2015: MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections 34

Clinical Trial Profile Snapshots 35

Appendix 134

Abbreviations 134

Definitions 134

Research Methodology 135

Secondary Research 135

About GlobalData 136

Disclaimer 137

Source 137

Source: http://www.researchbeam.com/clostridium-difficile-infections-clostridium-difficile-associated-disease-global-clinical-trials-review-h2-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

Prostate Cancer - Pipeline Review, 2015

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Prostate Cancer diagnostic tests pipeline products.

Enquiry about report: http://www.researchbeam.com/prostate-cancer-pipeline-review-2015-market/enquire-about-report

Scope

Extensive coverage of the Prostate Cancer diagnostic tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Prostate Cancer diagnostic tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Table of Content

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 20

2 Introduction 21

2.1 Prostate Cancer Overview 21

3 Products under Development 22

3.1 Prostate Cancer - Pipeline Products by Stage of Development 22

3.2 Prostate Cancer - Pipeline Products by Territory 23

4 Prostate Cancer - Pipeline Products under Development by Companies 27

4.1 Prostate Cancer Companies - Pipeline Products by Stage of Development 27

4.2 Prostate Cancer - Pipeline Products by Stage of Development 33

5 Prostate Cancer Companies and Product Overview 40

5.1 3D Biomatrix, LLC Company Overview 40

5.2 A&G Pharmaceutical, Inc. Company Overview 41

6 Prostate Cancer- Recent Developments 287

7 Appendix 347

7.1 Methodology 347

7.2 About GlobalData 349

Reasons to buy

The report enables you to

Formulate significant competitor information, analysis, and insights to improve R & D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Prostate Cancer diagnostic tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the products current stage of development, territory and estimated launch date

Source: http://www.researchbeam.com/prostate-cancer-pipeline-review-2015-market

About Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Web: http://www.researchbeam.com

Email Us: [email protected]

LinkedIn: http://www.linkedin.com/company/research-beam

#prostate cancer #prostate cancer market #prostate cancer market size #prostate cancer market share #prostate cancer market treatment #prostate cancer market trends #prostate cancer drug forecast #prostate cancer market growth #prostate cancer market future trends #prostate cancer market future #prostate cancer market analysis

Trending Blogs

Recently Viewed Blogs

Healthcare Reports